Expression and clinical significance of tumor abnormal protein in breast cancer / 中华内分泌外科杂志

Objective To explore the clinical application value of serum tumor abnormal protein (TAP)in early diagnosis of breast cancer.Methods The serum TAP level was determined in 53 hospitalized patients with breast cancer and 65 cases of normal physical examination population as the control group.We further compared the positive rate of TAP in the two groups and the expression level of TAP between different clinical pathological parameters in breast cancer group.Results There was no case of TAP positive in the control group,while the positive rate of TAP was as high as 83.02％ in breast cancer group.TAP positive rate of the patients with negative PR (100.00％) was significantly higher than that of PR positive patients (73.53％)(P=0.019).However there was no significant difference of TAP positive rate between patients with different ages,clinical stages,lymph node metastasis and the different expression of ER,C-erbB2 and Ki67.Conclusion It might be clinically valuable to use TAP expression level as a screening marker for breast cancer in combination with the breast cancer hormone PR.

Effect of RAD18-siRNA on proliferation and chemotherapy sensitivity of human esophageal squamous cell carcinoma ECA-109 cells / 浙江大学学报·医学版

To investigate the effect of RAD18-siRNA on cell proliferation and chemotherapy sensitivity of esophageal squamous cell carcinoma (ESCC) ECA-109 cells.RAD18-siRNA was transfected into human ECA-109 cells by Lipofectamine 3000. Quantitative PCR and Western blot were performed to detect RAD18 and CyclinD1 expression; CCK-8 assay was used to determine cell proliferation and chemotherapy drug sensitivity; flow cytometry was used to determine cell cycle. Correlation between RAD18 and CyclinD1 mRNA expression was analyzed by Pearson's correlation.Compared with non-transfected cells, the expression of RAD18 in RAD18-siRNA group was significantly decreased (<0.05). The cell proliferation was inhibited (<0.05) and the cell number of G1 phase was increased, G2/M phase cells decreased (<0.05) in RAD18-siRNA group. After treatment with different concentrations of cisplatin or 5-FU, the survival rate of the two cell groups was reduced (all<0.05), and the IC50 of RAD18-siRNA group was significantly lower than that of non-transfected group (<0.05). The mRNA expression of RAD18 was positively correlated with CyclinD1 expression in ESCC tissues(=0.478,<0.01).Down-regulated expression of RAD18 can decrease the cell proliferation and increase chemo-sensitivity of ESCC cells, and CyclinD1 may participate in the process.